Celltrion announced on Sept. 4 that it recently obtained sales approval for its Avastin (bevacizumab) biosimilar Vegzelma from the Australian Therapeutic Goods Administration (TGA).Celltrion has been granted sales approval for Vegzelma in Australia for the entire range of indications approved for Av
In August, exports outperformed expectations, surpassing seasonal factors such as summer vacations. The year-on-year decline in exports narrowed to single digits, and the decline in semiconductor exports to China also moderated compared to the previous month.According to the Ministry of Trade, Indus
On Aug. 31, Celltrion announced it has completed the product approval application for its autoimmune disease therapeutic “CT-P43,” a biosimilar of STELARA (ustekinumab), to Australia’s Therapeutic Goods Administration (TGA).Celltrion applied for CT-P43’s product approval in Australia for all indicat
On Aug. 22, JW Pharmaceutical announced that it has received approval for the Phase 3 clinical trial plan (IND) of the gout drug “Epanewrad” (code name URC102) from the Taiwan Food and Drug Administration (TFDA).Epanewrad, which JW Pharmaceutical is developing as an oral medication, is a uric acid e
In the ranking of the “Global 1000 Banks” published by the U.K. financial journal “The Banker,” which aggregates the performance of the previous year, six domestic banks, or financial groups, including KB Financial, Shinhan Financial, Korea Development Bank (KDB), Hana Financial, Woori Financial, an
On Aug. 17, GC Cell announced that its U.S. affiliate, Artiva Biotherapeutics, has received approval from the U.S. FDA for the Investigational New Drug application of its AB-101 natural killer (NK) cell therapy for lupus nephritis.Lupus is an autoimmune disease caused by immune system abnormalities
The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.2Q23 preview: Earnings to come in line with market expectationsWe now expect GC Biopharma to post consolidated sales of KRW437.1bn (+3.3% YoY) and operating profit of KRW20.3bn (+55.2% YoY, operating
GC Biopharma’s and SK plasma’s entries into Indonesia will accelerate this year. GC Biopharma is expected to finalize all procedures within this year after receiving approval for business rights related to the construction of a blood product factory and a technology transfer from the Indonesian gove
Samsung Electronics and Apple are set to compete in a new arena this time – the smart ring market.According to sources in the information and communication technology (ICT) industry on July 10, Samsung Electronics filed a trademark application for the Galaxy Circle with the Korean Intellectual Prope
SK plasma announced on June 28 that it has obtained product approval for its blood products (albumin and immunoglobulin) from the Health Sciences Authority (HSA) of Singapore, with full-scale production beginning in June.The company is to initiate the export of its initial quantity in the fourth qua
The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.All negatives reflected in 1Q23 earningsGC Biopharma reported disappointing earnings results in 1Q23, remaining in the red for the second quarter. Sales declined by 16% YoY to KRW349.5bn due to a high
GC Biopharma Corp. announced on June 1 that it has received final approval from the Indonesian Ministry of Health and Welfare for a blood product plant construction and technology transfer project.The Indonesian government carried out the selection process for a contractor for the construction and t
Samsung Display has rolled out the Rollable Flex and Sensor OLED Display, innovative technologies that could reshape the Organic Light Emitting Diodes (OLED) industry paradigm.Samsung Display announced its participation in Display Week 2023 held in Los Angeles, California, from May 23 to 25 (local t
Just in six months since launching the GlucoMen Day PUMP, a blood sugar control solution, in Europe, EOFlow is facing a sales suspension on the product. Insulet, the No. 1 insulin pump company in Germany, has been granted a preliminary injunction related to a patent in Germany, halting local sales o
Six months ago, the Korea-based medical device manufacturer EOFlow launched a new product in Germany. Now, on March 24, the company faces a patent dispute from the top insulin pump manufacturer in the country and a sales suspension, with no word on when or if they will be able to sell again.EOFlow h
Just six months since launching the GlucoMen Day PUMP, a blood sugar control solution, in Europe, EOFlow is facing sales suspension of the product. Insulet, the No. 1 insulin pump company in Germany, has been granted a preliminary injunction related to a patent in Germany, halting local sales of the
SK Plasma announced on March 24 that SK Plasma CEO Kim Seung-joo signed a joint declaration to build and operate a blood products plant in Indonesia at an event attended by Korean Minister of Health and Welfare Cho Kyu-hong and Indonesian Health Minister Budi Gunadi Sadikin in honor of the 50th anni
SK Plasma announced on March 8 that it received final approval for the construction of a plasma fractionation plant from the Ministry of Health of Indonesia.This export is a result of collaboration between the Ministry of Health and Welfare of Korea and the Korean Embassy in Indonesia since 2019. It
SK Plasma will build a 300-billion-won blood plant in Indonesia. The plant will be capable of producing 1 million liters of blood products per year. The company plans to break ground on the plant in 2023 and complete it two years later.According to industry sources on March 7, SK Plasma has recently
GC Biopharma announced on Feb. 28 that it has signed an asset purchase agreement with Catalyst Biosciences, a US drug developer, for a pipeline for a coagulation disease.Through this contract, GC Biopharma will acquire a total of three pipelines, including Marzeptacog alfa (MarzAA) under development